Novo Integrated Sciences’ Purchase and Sale Agreement to Acquire Ophir Collection Receives Court Approval

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the United States District Court for the Central District of California has approved the Purchase and Sale Agreement (“PSA”) which provides for the Company to acquire a certain collection of 43 gemstones, 42 of which are certified by the Gemological Institute of America, known as the “Ophir Collection,” for $60,000,000. The PSA was entered into on November 21, 2023, between the Company and Blake Alsbrook (“Seller”), solely in Seller’s capacity as Court-appointed Successor Receiver in Ocean Thermal Energy Corporation v. C. Robert Coe II, et al., United States District Court for the Central District of California, Case No. 2:19-cv-04299 VAP (JPRx). The PSA was previously disclosed by the Company in a Form 8-K filing, dated November 27, 2023.

Robert Mattacchione, Novo’s CEO and Chairman of the Board, stated, “The magnitude of the world-famous Ophir Collection is expected to optimize the company’s monetization opportunity resulting in a significant cash surplus position while providing the company with both debt retirement and growth initiative solutions. Securing the financing required for the execution of this transaction has been a significant undertaking and we look forward to calling the collection ours.”

About Novo Integrated Sciences, Inc.

Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.

We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.